High-dose 131I-mIBG as consolidation therapy in pediatric patients with relapsed neuroblastoma and ganglioneuroblastoma: the Japanese experience
| Autor: | Hiroshi Mori, Rie Kuroda, Raita Araki, Seigo Kinuya, Taizo Wada, Anri Inaki, Takafumi Yamase, Satoru Watanabe, Toshihiro Fujiki, Norihito Akatani, Shintaro Saito, Ryosei Nishimura, Hiroshi Wakabayashi, Yuji Kunita, Yasuhiro Ikawa, Tomo Hiromasa, Daiki Kayano |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty medicine.diagnostic_test business.industry General Medicine Multimodality Therapy medicine.disease Scintigraphy 030218 nuclear medicine & medical imaging Radiation exposure Consolidation therapy 03 medical and health sciences 0302 clinical medicine Tumor progression 030220 oncology & carcinogenesis Internal medicine medicine Overall survival Radiology Nuclear Medicine and imaging business Relapsed Neuroblastoma Ganglioneuroblastoma |
| Zdroj: | Annals of Nuclear Medicine. 34:840-846 |
| ISSN: | 1864-6433 0914-7187 |
| Popis: | Children with relapsed neuroblastoma have a poor prognosis despite modern multimodality therapy. Novel and more effective therapeutic strategies are required for relapsed neuroblastoma. We retrospectively examined the utility of consolidation therapy with high-dose 131I-meta-iodo-benzyl-guanidine (131I-mIBG) in relapsed neuroblastoma or ganglioneuroblastoma patients with complete response (CR) to induction therapy as demonstrated by diagnostic 123I-mIBG scintigraphy. Between December 2009 and 2014, five patients with relapsed neuroblastoma and one with relapsed ganglioneuroblastoma received high-dose 131I-mIBG therapy. Overall and progression-free survival rates at five years after 131I-mIBG therapy were analyzed by the Kaplan–Meier method. During follow-up, three children showed no signs of disease relapse, whereas three died. One child without a relapse died from post-transplant side effects, and two children with a relapse died owing to tumor progression. The 5-year progression-free and overall survival rates after 131I-mIBG therapy were 44% and 67%, respectively. Consolidation therapy with high-dose 131I-mIBG for patients with 2nd CR showed good overall and progression-free survival. While the risks of radiation exposure must be considered, high-dose 131I-mIBG therapy as consolidation therapy needs to be further investigated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink